660 Phase 2 Study to evaluate the triplet combination of pemetrexed plus etrumadenant and zimberelimab in patients with previously treated advanced or MTAP-deficient metastatic urothelial carcinoma (mUC)

• Linghua Wang,
• Jianjun Gao,
• Wei Qiao,
• Arlene Siefker-Radtke,
• Matthew Campbell,
• Amishi Shah,
• Rahul Sheth,
• Omar Alhalabi,
• Sangeeta Goswami,
• Charles Guo,
• Sergio P Klimkowsky,
• Tharekeswara Bathala,
• Jianfeng Chen,
• Xinmiao Yan,
• Ana Adriazola

Affiliations

Linghua Wang

2The University of Texas MD Anderson Cancer Center, Sugar Land, TX, USA

Jianjun Gao

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Wei Qiao

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Arlene Siefker-Radtke

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Matthew Campbell

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Amishi Shah

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Rahul Sheth

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Omar Alhalabi

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Sangeeta Goswami

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Charles Guo

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Sergio P Klimkowsky

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Tharekeswara Bathala

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Jianfeng Chen

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Xinmiao Yan

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Ana Adriazola

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA